Adam L Boxer

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2976977/publications.pdf

Version: 2024-02-01

160 papers	22,878 citations	16451 64 h-index	9589 142 g-index
167 all docs	167 docs citations	167 times ranked	21601 citing authors

#	Article	IF	Citations
1	Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS. Neuron, 2011, 72, 245-256.	8.1	4,176
2	Genetic meta-analysis of diagnosed Alzheimerâ€™s disease identifies new risk loci and implicates Aî², tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	21.4	1,962
3	Criteria for the diagnosis of corticobasal degeneration. Neurology, 2013, 80, 496-503.	1.1	1,445
4	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Movement Disorders, 2017, 32, 853-864.	3.9	1,402
5	ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature, 2017, 549, 523-527.	27.8	852
6	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	21.4	783
7	Diagnostic value of plasma phosphorylated tau181 in Alzheimerâ€™s disease and frontotemporal lobar degeneration. Nature Medicine, 2020, 26, 387-397.	30.7	471
8	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. JAMA Neurology, 2019, 76, 1035.	9.0	455
9	At the interface of sensory and motor dysfunctions and Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 70-98.	0.8	420
10	Clinicopathological correlations in corticobasal degeneration. Annals of Neurology, 2011, 70, 327-340.	5.3	367
11	Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease. Neurology, 2015, 85, 40-47.	1.1	355
12	Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain, 2015, 138, 2020-2033.	7.6	319
13	Patterns of Brain Atrophy That Differentiate Corticobasal Degeneration Syndrome From Progressive Supranuclear Palsy. Archives of Neurology, 2006, 63, 81.	4.5	315
14	Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurology, The, 2017, 16, 552-563.	10.2	303
15	Discriminative Accuracy of [¹⁸F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA - Journal of the American Medical Association, 2018, 320, 1151.	7.4	298
16	Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer's disease. FASEB Journal, 2016, 30, 4141-4148.	0.5	281
17	Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurology, The, 2014, 13, 676-685.	10.2	245
18	Clinicopathological correlations in behavioural variant frontotemporal dementia. Brain, 2017, 140, 3329-3345.	7.6	226

#	Article	IF	Citations
19	Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurology, The, 2021, 20, 739-752.	10.2	220
20	Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Annals of Neurology, 2014, 75, 116-126.	5.3	213
21	Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2013, 12, 149-156.	10.2	204
22	Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Human Molecular Genetics, 2012, 21, 3500-3512.	2.9	198
23	NIH EXAMINER: Conceptualization and Development of an Executive Function Battery. Journal of the International Neuropsychological Society, 2014, 20, 11-19.	1.8	190
24	Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?. Movement Disorders, 2017, 32, 955-971.	3.9	179
25	Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72 -associated amyotrophic lateral sclerosis. Science Translational Medicine, 2017, 9, .	12.4	179
26	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology, The, 2020, 19, 145-156.	10.2	175
27	Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease. JAMA Neurology, 2014, 71, 1394.	9.0	166
28	Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Annals of Clinical and Translational Neurology, 2016, 3, 216-225.	3.7	163
29	Multisite study of the relationships between antemortem [¹¹C]PIBâ€PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology. Alzheimer's and Dementia, 2019, 15, 205-216.	0.8	155
30	Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease. JAMA Neurology, 2021, 78, 961.	9.0	148
31	Altered network connectivity in frontotemporal dementia with C9orf72 hexanucleotide repeat expansion. Brain, 2014, 137, 3047-3060.	7.6	140
32	Features of Patients With Nonfluent/Agrammatic Primary Progressive Aphasia With Underlying Progressive Supranuclear Palsy Pathology or Corticobasal Degeneration. JAMA Neurology, 2016, 73, 733.	9.0	131
33	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. Movement Disorders, 2017, 32, 995-1005.	3.9	121
34	Distinct Subtypes of Behavioral Variant Frontotemporal Dementia Based on Patterns of Network Degeneration. JAMA Neurology, 2016, 73, 1078.	9.0	115
35	Associations between [¹⁸ F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample. Neurology, 2018, 90, e282-e290.	1.1	113
36	An Open-label Study of Memantine Treatment in 3 Subtypes of Frontotemporal Lobar Degeneration. Alzheimer Disease and Associated Disorders, 2009, 23, 211-217.	1.3	110

#	Article	IF	Citations
37	Therapy and clinical trials in frontotemporal dementia: past, present, and future. Journal of Neurochemistry, 2016, 138, 211-221.	3.9	109
38	Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity. JAMA Neurology, 2021, 78, 1345.	9.0	109
39	Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. Lancet Neurology, The, 2019, 18, 549-558.	10.2	108
40	Cinguloparietal Atrophy Distinguishes Alzheimer Disease From Semantic Dementia. Archives of Neurology, 2003, 60, 949.	4.5	106
41	Clinical Features of Frontotemporal Dementia. Alzheimer Disease and Associated Disorders, 2005, 19, S3-S6.	1.3	102
42	Divergent CSF Â alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 244-250.	1.9	101
43	18F-flortaucipir PET to autopsy comparisons in Alzheimerâ€™s disease and other neurodegenerative diseases. Brain, 2020, 143, 3477-3494.	7.6	100
44	Comorbid neuropathological diagnoses in early versus late-onset Alzheimerâ€™s disease. Brain, 2021, 144, 2186-2198.	7.6	100
45	Saccade Abnormalities in Autopsy-Confirmed Frontotemporal Lobar Degeneration and Alzheimer Disease. Archives of Neurology, 2012, 69, 509.	4.5	97
46	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	10.2	97
47	Rescue of a lysosomal storage disorder caused by Grn loss of function with a brain penetrant progranulin biologic. Cell, 2021, 184, 4651-4668.e25.	28.9	97
48	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. Movement Disorders, 2019, 34, 1228-1232.	3.9	93
49	Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia. Acta Neuropathologica, 2017, 133, 825-837.	7.7	90
50	4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration. Acta Neuropathologica, 2020, 139, 63-77.	7.7	89
51	Intrinsic connectivity network disruption in progressive supranuclear palsy. Annals of Neurology, 2013, 73, 603-616.	5.3	88
52	Medial Versus Lateral Frontal Lobe Contributions to Voluntary Saccade Control as Revealed by the Study of Patients with Frontal Lobe Degeneration. Journal of Neuroscience, 2006, 26, 6354-6363.	3.6	85
53	A152T tau allele causes neurodegeneration that can be ameliorated in a zebrafish model by autophagy induction. Brain, 2017, 140, 1128-1146.	7.6	84
54	Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease. Neurology, 2021, 96, e671-e683.	1.1	84

#	Article	IF	Citations
55	Oxytocin for frontotemporal dementia. Neurology, 2015, 84, 174-181.	1.1	83
56	Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome. JAMA Neurology, 2020, 77, 215.	9.0	81
57	Utility of the global CDR^{Â®} plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium. Alzheimer's and Dementia, 2020, 16, 106-117.	0.8	81
58	Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease. JAMA Neurology, 2020, 77, 632.	9.0	80
59	Retraining speech production and fluency in non-fluent/agrammatic primary progressive aphasia. Brain, 2018, 141, 1799-1814.	7.6	79
60	Increased prevalence of autoimmune disease within C9 and FTD/MND cohorts. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e301.	6.0	78
61	Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy. Science Translational Medicine, 2017, 9, .	12.4	78
62	Joint genome-wide association study of progressive supranuclear palsy identifies novel susceptibility loci and genetic correlation to neurodegenerative diseases. Molecular Neurodegeneration, 2018, 13, 41.	10.8	77
63	Frontotemporal dementia with the V337M MAPT mutation. Neurology, 2017, 88, 758-766.	1.1	76
64	CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology, 2018, 90, e273-e281.	1.1	75
65	Frontotemporal Dementia Treatment: Current Symptomatic Therapies and Implications of Recent Genetic, Biochemical, and Neuroimaging Studies. Alzheimer Disease and Associated Disorders, 2007, 21, S79-S87.	1.3	74
66	Cognition and neuropsychiatry in behavioral variant frontotemporal dementia by disease stage. Neurology, 2016, 86, 600-610.	1.1	73
67	Promoting tau secretion and propagation by hyperactive p300/CBP via autophagy-lysosomal pathway in tauopathy. Molecular Neurodegeneration, 2020, 15, 2.	10.8	69
68	Progression of brain atrophy in PSP and CBS over 6 months and 1 year. Neurology, 2016, 87, 2016-2025.	1.1	65
69	Longitudinal multimodal imaging and clinical endpoints for frontotemporal dementia clinical trials. Brain, 2019, 142, 443-459.	7.6	65
70	Targeting tau: Clinical trials and novel therapeutic approaches. Neuroscience Letters, 2020, 731, 134919.	2.1	63
71	Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nature Medicine, 2021, 27, 1451-1457.	30.7	63
72	Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations. Lancet Neurology, The, 2022, 21, 258-272.	10.2	63

#	Article	IF	Citations
73	Frontotemporal degeneration, the next therapeutic frontier: Molecules and animal models for frontotemporal degeneration drug development. Alzheimer's and Dementia, 2013, 9, 176-188.	0.8	58
74	Off-Label Medication Use in Frontotemporal Dementia. American Journal of Alzheimer's Disease and Other Dementias, 2010, 25, 128-133.	1.9	57
75	Patterns of Striatal Degeneration in Frontotemporal Dementia. Alzheimer Disease and Associated Disorders, 2013, 27, 74-83.	1.3	55
76	Distinct spatiotemporal patterns of neuronal functional connectivity in primary progressive aphasia variants. Brain, 2017, 140, 2737-2751.	7.6	53
77	Longitudinal magnetic resonance imaging in progressive supranuclear palsy: A new combined score for clinical trials. Movement Disorders, 2017, 32, 842-852.	3.9	52
78	Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. Neurology, 2021, 96, e2296-e2312.	1.1	52
79	Regional correlations between [11 C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort. NeuroImage: Clinical, 2017, 13, 130-137.	2.7	50
80	Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration. Neurology, 2022, 98, .	1.1	49
81	The advantages of frontotemporal degeneration drug development (partÂ2Âof frontotemporal) Tj ETQq1 1 0.784314 rgBT /Overlock	0.8	48
82	Abhorring the vacuum: use of Alzheimerâ€™s disease medications in frontotemporal dementia. Expert Review of Neurotherapeutics, 2011, 11, 709-717.	2.8	47
83	Longitudinal white matter change in frontotemporal dementia subtypes and sporadic late onset Alzheimer's disease. NeuroImage: Clinical, 2017, 16, 595-603.	2.7	45
84	New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures. Alzheimer's and Dementia, 2020, 16, 131-143.	0.8	45
85	Plasma Glial Fibrillary Acidic Protein Levels Differ Along the Spectra of Amyloid Burden and Clinical Disease Stage1. Journal of Alzheimer's Disease, 2020, 78, 265-276.	2.6	43
86	Current directions in tau research: Highlights from Tau 2020. Alzheimer's and Dementia, 2022, 18, 988-1007.	0.8	42
87	Altered topology of the functional speech production network in non-fluent/agrammatic variant of PPA. Cortex, 2018, 108, 252-264.	2.4	41
88	Progression of Microstructural Degeneration in Progressive Supranuclear Palsy and Corticobasal Syndrome: A Longitudinal Diffusion Tensor Imaging Study. PLoS ONE, 2016, 11, e0157218.	2.5	40
89	Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory. Annals of Clinical and Translational Neurology, 2018, 5, 1250-1263.	3.7	40
90	Longitudinal structural and metabolic changes in frontotemporal dementia. Neurology, 2020, 95, e140-e154.	1.1	39

#	Article	IF	Citations
91	Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration. Alzheimer's and Dementia, 2020, 16, 37-48.	0.8	38
92	Downregulation of exosomal miR-204-5p and miR-632 as a biomarker for FTD: a GENFI study. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 851-858.	1.9	37
93	Early vs late age at onset frontotemporal dementia and frontotemporal lobar degeneration. Neurology, 2018, 90, e1047-e1056.	1.1	36
94	Sleepless Night and Day, the Plight of Progressive Supranuclear Palsy. Sleep, 2017, 40, .	1.1	35
95	Network-driven plasma proteomics expose molecular changes in the Alzheimerâ€™s brain. Molecular Neurodegeneration, 2016, 11, 31.	10.8	34
96	<scp>Openâ€Label</scp> Phase 1 Futility Studies of Salsalate and Young Plasma in Progressive Supranuclear Palsy. Movement Disorders Clinical Practice, 2020, 7, 440-447.	1.5	34
97	Diagnostic Accuracy of Amyloid versus ¹⁸Fâ€Fluorodeoxyglucose Positron Emission Tomography in <scp>Autopsyâ€Confirmed</scp> Dementia. Annals of Neurology, 2021, 89, 389-401.	5.3	34
98	Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve. Alzheimer's and Dementia, 2021, 17, 1329-1341.	0.8	34
99	Right temporal degeneration and socioemotional semantics: semantic behavioural variant frontotemporal dementia. Brain, 2022, 145, 4080-4096.	7.6	34
100	Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials. Parkinsonism and Related Disorders, 2016, 28, 41-48.	2.2	33
101	Genome-wide association study identifies MAPT locus influencing human plasma tau levels. Neurology, 2017, 88, 669-676.	1.1	33
102	Tracking disease progression in familial and sporadic frontotemporal lobar degeneration: Recent findings from ARTFL and LEFFTDS. Alzheimer's and Dementia, 2020, 16, 71-78.	0.8	33
103	Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography. Alzheimer's Research and Therapy, 2015, 7, 8.	6.2	32
104	An 8â€week, openâ€label, doseâ€finding study of nimodipine for the treatment of progranulin insufficiency from GRN gene mutations. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 507-512.	3.7	32
105	Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIHâ€EXAMINER as a potential clinical trial endpoint. Alzheimer's and Dementia, 2020, 16, 11-21.	0.8	32
106	The longitudinal evaluation of familial frontotemporal dementia subjects protocol: Framework and methodology. Alzheimer's and Dementia, 2020, 16, 22-36.	0.8	32
107	Neuropathological correlates of structural and functional imaging biomarkers in 4-repeat tauopathies. Brain, 2019, 142, 2068-2081.	7.6	30
108	Thalamo-cortical network hyperconnectivity in preclinical progranulin mutation carriers. NeuroImage: Clinical, 2019, 22, 101751.	2.7	30

#	Article	IF	Citations
109	Proposed research criteria for prodromal behavioural variant frontotemporal dementia. Brain, 2022, 145, 1079-1097.	7.6	30
110	Evidence of corticofugal tau spreading in patients with frontotemporal dementia. Acta Neuropathologica, 2020, 139, 27-43.	7.7	29
111	Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care. Frontiers in Neurology, 2021, 12, 694872.	2.4	29
112	The functional oculomotor network and saccadic cognitive control in healthy elders. NeuroImage, 2014, 95, 61-68.	4.2	27
113	Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration. Alzheimer's and Dementia, 2020, 16, 49-59.	0.8	27
114	The impact of demographic, clinical, genetic, and imaging variables on tau PET status. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2245-2258.	6.4	27
115	Advancing functional dysconnectivity and atrophy in progressive supranuclear palsy. NeuroImage: Clinical, 2017, 16, 564-574.	2.7	26
116	Four-Repeat Tauopathies: Current Management and Future Treatments. Neurotherapeutics, 2020, 17, 1563-1581.	4.4	24
117	Revised Self-Monitoring Scale. Neurology, 2020, 94, e2384-e2395.	1.1	23
118	Dataâ€driven regions of interest for longitudinal change in three variants of frontotemporal lobar degeneration. Brain and Behavior, 2017, 7, e00675.	2.2	22
119	Rates of lobar atrophy in asymptomatic MAPT mutation carriers. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 338-346.	3.7	22
120	Targeting tauopathies for therapeutic translation. Nature Reviews Neurology, 2016, 12, 74-76.	10.1	21
121	Therapeutic trial design for frontotemporal dementia and related disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 412-423.	1.9	21
122	Brain volumetric deficits in MAPT mutation carriers: a multisite study. Annals of Clinical and Translational Neurology, 2021, 8, 95-110.	3.7	21
123	Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders. Cell Reports Medicine, 2022, 3, 100607.	6.5	21
124	Subcortical Neuronal Correlates of Sleep in Neurodegenerative Diseases. JAMA Neurology, 2022, 79, 498.	9.0	20
125	Clinical Trials: Past, Current, and Future for Atypical Parkinsonian Syndromes. Seminars in Neurology, 2014, 34, 225-234.	1.4	19
126	Rates of Brain Atrophy Across Disease Stages in Familial Frontotemporal Dementia Associated With MAPT, GRN, and C9orf72 Pathogenic Variants. JAMA Network Open, 2020, 3, e2022847.	5.9	19

#	Article	IF	Citations
127	Rest-activity rhythm disruption in progressive supranuclear palsy. Sleep Medicine, 2016, 22, 50-56.	1.6	18
128	Effect of the Histone Deacetylase Inhibitor FRM-0334 on Progranulin Levels in Patients With Progranulin Gene Haploinsufficiency. JAMA Network Open, 2021, 4, e2125584.	5.9	18
129	Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration. JAMA Network Open, 2022, 5, e229588.	5.9	18
130	Hepatic and renal function impact concentrations of plasma biomarkers of neuropathology. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, .	2.4	16
131	Development and validation of the Uniform Data Set (v3.0) executive function composite score (UDS3â€EF). Alzheimer's and Dementia, 2021, 17, 574-583.	0.8	15
132	Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers. Neurobiology of Aging, 2019, 83, 54-62.	3.1	14
133	Lower White Matter Volume and Worse Executive Functioning Reflected in Higher Levels of Plasma GFAP among Older Adults with and Without Cognitive Impairment. Journal of the International Neuropsychological Society, 2022, 28, 588-599.	1.8	14
134	Cognitive deficits in progressive supranuclear palsy on the Repeatable Battery for the Assessment of Neuropsychological Status. Journal of Clinical and Experimental Neuropsychology, 2019, 41, 469-475.	1.3	12
135	Progressive supranuclear palsy and primary lateral sclerosis secondary to globular glial tauopathy: a case report and a practical theoretical framework for the clinical prediction of this rare pathological entity. Neurocase, 2020, 26, 91-97.	0.6	12
136	Diagnostic Utility of Measuring Cerebral Atrophy in the Behavioral Variant of Frontotemporal Dementia and Association With Clinical Deterioration. JAMA Network Open, 2021, 4, e211290.	5.9	12
137	Recognition memory and divergent cognitive profiles in prodromal genetic frontotemporal dementia. Cortex, 2021, 139, 99-115.	2.4	12
138	The Cortical Basal ganglia Functional Scale (CBFS): Development and preliminary validation. Parkinsonism and Related Disorders, 2020, 79, 121-126.	2.2	11
139	Lack of Association Between the CCR5-delta32 Polymorphism and Neurodegenerative Disorders. Alzheimer Disease and Associated Disorders, 2020, 34, 244-247.	1.3	11
140	Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale. Movement Disorders, 2016, 31, 1574-1577.	3.9	10
141	Plasma P-tau181 and P-tau217 in Patients With Traumatic Encephalopathy Syndrome With and Without Evidence of Alzheimer Disease Pathology. Neurology, 2022, 99, .	1.1	10
142	FTLD Treatment: Current Practice and Future Possibilities. Advances in Experimental Medicine and Biology, 2021, 1281, 297-310.	1.6	9
143	The contribution of behavioral features to caregiver burden in FTLD spectrum disorders. Alzheimer's and Dementia, 2022, 18, 1635-1649.	0.8	9
144	A Modified Progressive Supranuclear Palsy Rating Scale for Virtual Assessments. Movement Disorders, 2022, 37, 1265-1271.	3.9	9

#	Article	IF	Citations
145	Peripheral Innate Immune Activation Correlates With Disease Severity in GRN Haploinsufficiency. Frontiers in Neurology, 2019, 10, 1004.	2.4	7
146	Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. Parkinsonism and Related Disorders, 2019, 60, 138-145.	2.2	7
147	Frequency of the TREM2 R47H Variant in Various Neurodegenerative Disorders. Alzheimer Disease and Associated Disorders, 2019, 33, 327-330.	1.3	6
148	Associations Between Amantadine Usage, Gait, and Cognition in PSP: A post-hoc Analysis of the Davunetide Trial. Frontiers in Neurology, 2020, 11, 606925.	2.4	6
149	Cognitive decline on the Repeatable Battery for the Assessment of Neuropsychological Status in progressive supranuclear palsy. Clinical Neuropsychologist, 2020, 34, 529-540.	2.3	5
150	Primary chronic traumatic encephalopathy in an older patient with late-onset AD phenotype. Neurology: Clinical Practice, 2015, 5, 475-479.	1.6	4
151	O4â€02â€01: PHASE 2A RANDOMIZED, DOUBLEâ€BLIND, PLACEBOâ€CONTROLLED TRIAL OF THE HISTONE DEACETYLASE INHIBITOR (HDACI), FRMâ€0334, IN ASYMPTOMATIC CARRIERS OF, OR PATIENTS WITH FRONTOTEMPORAL LOBAR DEGENERATION (FTLD) DUE TO, PROGRANULIN GENE MUTATIONS. Alzheimer's and Dementia, 2019, 15, P1231.	0.8	4
152	The Frontotemporal Dementia Prevention Initiative: Linking Together Genetic Frontotemporal Dementia Cohort Studies. Advances in Experimental Medicine and Biology, 2021, 1281, 113-121.	1.6	3
153	Tau Mutations as a Novel Risk Factor for Cancerâ€"Letter. Cancer Research, 2018, 78, 6523-6524.	0.9	2
154	Frontotemporal lobar degeneration. , 2005, , 481-493.		1
155	Digital Cognitive Assessments for Dementia: Digital assessments may enhance the efficiency of evaluations in neurology and other clinics. Practical Neurology, 2020, 2020, 24-45.	0.5	1
156	Disease progression models of familial frontotemporal lobar degeneration and the temporal ordering of biomarker changes in an international cohort. Alzheimer's and Dementia, 2021, 17, .	0.8	1
157	O2â€14â€06: DIFFERENCES BETWEEN SPORADIC AND FAMILIAL BEHAVIORAL VARIANT FTD IN ADVANCING RESEARCH AND TREATMENT FOR FTLD (ARTFL) CLINICAL RESEARCH CONSORTIUM. Alzheimer's and Dementia, 2018, 14, P658.	0.8	0
158	Tau therapeutics: Clinical development status and future directions. Alzheimer's and Dementia, 2020, 16, e044852.	0.8	0
159	Clinical Trial Development in Frontotemporal Lobar Degeneration. , 2022, , 216-231.		0
160	Sensitivity of the Social Behavior Observer Checklist to Early Symptoms of Patients With Frontotemporal Dementia. Neurology, 2022, , 10.1212/WNL.0000000000200582.	1.1	0